FDA Advisers Recommend Approval of New Shingles Vaccine — Physician’s First Watch

Medical News |
September 14, 2017

FDA Advisers Recommend Approval of New Shingles Vaccine

By the Editors

An FDA advisory panel voted 11-0 on Wednesday in favor of approving the Shingrix herpes zoster vaccine for adults aged 50 and older, Reuters reports.

In clinical trials, the new vaccine conferred greater protection against herpes zoster among older adults, relative to the currently marketed zoster vaccine, Zostavax. In particular, 4 years after immunization, Shingrix was about 90% effective in adults older than 70, while the efficacy of Zostavax waned with time, according to Reuters.

The FDA is not required to follow the advice of its advisers, but it usually does.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.